reiter market outperform rate price target
corpor base discount earn per share revenu multipl
analysi week report posit result trial
ruxolitinib rux cream mild moder atop dermat ad addit eli lilli
nc announc phase breeze-
trial baricitinib patient moder sever ad met pre-
specifi primari endpoint discuss result well long-term
prospect rux franchis manag follow-up call provid
key highlight rux pois gener sale
pemigatinib obtain prioriti review may pdufa data novarti
nv nc file sr-agvhd world-wide posit phase result come
compani dermatolog franchis post-tafasitamab cash posit
pro forma continu recommend share
takeaway discuss manag
continu grow rux franchis take action protect
futur revenu jakafi enjoy steadi increas market penetr
approv indic myelofibrosi mf
market penetr graft-versus-host diseas gvhd
patient drug figur expect pv gvhd growth
outpac mf call manag learn
mf patient remain nave jakafi treatment leav consider
growth potenti indic well manag also detail potenti
strategi extend rux franchis well beyond jakafi
once-a-day qd rux track potenti approv
on-going bioavail bioequival ba/b studi compar qd
rux current twice-daili bid rux healthi volunt data
expect year new formul approv via
rout patent protect could extend although gener
bid competit could still erod potenti market share post jakafi
combin rux even promis qd formul
rux potenti combin therapi could improv efficaci
and/or safeti profil rux monotherapi extend effect
patent life chief among combin rux plu parsaclisib incyt
inhibitor show signific reduct spleen volum
qd dose parsaclisib bid dose rux figur pivot trial
test combin mf patient current prepar initi
data phase ii trial expect
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
also test rux combin pim inhibitor proof-of-concept
poc trial underway data expect bet inhibitor poc trial
expect initi inhibitor poc trial expect
initi combin could later date
combin single-pil formul extend patent protect
high hope upcom tafasitamab plu parsaclisib trial part
recent collabor licens agreement morphosi mor mo
pt butler see note respons initi combin trial
tafasitamab plu parsaclisib r/r nhl cll dose-escal dose-
expans trial expect begin year excit see trial
pan given impress result seen tafasitamab plu idelalisib
inhibitor like parsaclisib cosmo trial although r/r cll
patient treat trial achiev complet respons cr
achiev partial respons pr total overal respons rate orr
figur total patient jakafi
preview
jakavi sale novarti report jakavi sale increas
jakavi sale increas growth driven increas
demand mf pv
olumi sale report olumi sale
ex-u increas olumi sale
ex-u repres increas ex-u revenu driven
increas volum off-set unfavor foreign exchang rate lower price
slight increas expect royalti jmp estim within guidanc follow
impress perform jakavi olumi increas estim product
royalti jakavi olumi revenu figur set
report result next week confer call februari estimate dial-in
confer id number highlight continu confid jakafi
expect achiev sale well estim within
figur jmp estim million except per share data
figur jmp estim million except per share data
week announc posit result pivot trial rux cream
mild-to-moder ad phase trial baricitinib
moderate-to-sever ad bring compani dermatolog franchis focu
one two ident pivot trial rux cream ad meet primari endpoint
expect readout top-lin result quarter optimist ultim chanc
approv eli lilli charg develop market baricitinib olumi
return tier royalti rheumatoid arthriti ra
approv ad result help highlight potenti jak inhibitor dermatolog
said expect rux cream compar favor competitor eucrisa
baricitinib competitor dupix
pivot trial met primari endpoint significantli ad patient
treat rux cream bid achiev point improv
investig global assess iga score week treat
placebo compani provid addit detail press releas hold data
present upcom scientif meet howev note efficaci
safeti data consist present earlier phase trial look back
data week patient improv iga score point primari
endpoint patient achiev key secondari endpoint treat
rux cream bid compar placebo figur
rux cream versu eucrisa eucrisa approv use iga score improv week
compar placebo consequ focu week data rux cream compar
figur look percentag patient achiev necessari iga score
improv iga respond rux cream outperform eucrisa versu
trial trial notabl howev patient placebo vehicl arm saw
improv eucrisa trial trial trial
phase ii rux cream trial could indic patient enrol eucrisa
trial healthier enrol rux cream trial potenti inflat eucrisa
compar respons rate order account differ drug
placebo arm respons compar case delta rux cream far
better delta eucrisa trial
move safeti drug appear well toler patient howev incyt
manag note discuss patient physician reveal
eucrisa tendenc caus burn sting sensat appli run
counter fda label eucrisa indic patient experi
applic site pain either case view rux cream compar superior
product eucrisa
rux cream market opportun base research total address market
rux cream atop dermat ad vitiligo could reach notabl
includ vitiligo patient activ seek treatment see note
detail last rux cream data vitiligo intens direct-to-consum
campaign like part market strategi would surpris abl
grow market beyond risk-adjust peak sale ad estim
bull-cas scenario base-cas scenario current exclud revenu
dermatolog franchis figur notabl believ ad peak sale estim
particular conserv consid abl achiev eucrisa
sale alon second full year launch figur given mani view
mf/ pv market opportun began sell rux franchis
like gener close revenu world-wide believ investor
remain optimist abil grow domin dermatolog space
phase trial meet primari endpoint phase
met primari endpoint least improv eczema area
sever week moderate-to-sever ad patient unabl continu
take cyclosporin highest dose test mg patient achiev
compar placebo group lower dose
mg mg respect dose-depend improv also seen valid
investig global assess viga mg group mg group
mg group placebo achiev score clear almost clear week
mg baricitinib group also larger proport patient achiev
improv itch nr lower dose mg mg placebo
notabl drug well toler venou thromboembol event death
report import given one patient experienc pulmonari embol
trial three day data realiz eli lilli announc
trial met primari endpoint least improv well
trial also report venou thromboembol event death lilli recent submit
baricitinib ad approv eu japan plan submit approv
year
baricitinib versu dupix unfortun higher dose mg baricitinib plu topic
corticosteroid data achiev improv iga less
impress compar dupix plu data wherein achiev
improv iga ad fact baricitinib fall short efficaci dupix
fewer potenti safeti concern fda express concern use higher dose
jak inhibitor suggest us dupix like maintain signific
competit advantag baricitinib approv still believ market exist patient
respond dupix develop antibodi advers reaction dupix
treatment particularli avers inject medic prefer oral
altern seem recogn base commentari recent earn call
baricitinib promis patient fear inject regardless
develop commerci eli lilli hand view success
baricitinib materi import move forward
figur phase ii result rux cream ad
figur rux cream eucrisa comparison
figur market model summari rux cream ad
rux cream bid bid vs vehicl deltaphas ii rux cream trialeucrisa trial trial iga report thousand total address patient popul us project annual wac us total address market opportun us total address patient popul eu project annual wac eu total address market opportun eu total market opportun us eu year market penetr achiev us project market penetr us probabl success us risk-adjust revenu us year market penetr achiev eu project market penetr eu probabl success eu risk-adjust revenu eu total risk-adjust revenu creamatop dermat mild incyt corpor
figur market model summari rux cream vitiligo
report thousand total address patient popul us project annual wac us total address market opportun us total address patient popul eu project annual wac eu total address market opportun eu total market opportun us eu year market penetr achiev us project market penetr us probabl success us risk-adjust revenu us year market penetr achiev eu project market penetr eu probabl success eu risk-adjust revenu eu total risk-adjust revenu incyt corpor
potenti approv pemigatinib second-lin mutant cholangiocarcinoma
potenti report updat phase ii data pemigatinib bladder cancer
rux itacitinib franchis
potenti report phase result trial
potenti initi phase trial rux plu combin mf
potenti report healthi volunt data once-a-day rux
potenti report result itacitinib phase studi sn-cgvhd
potenti report top-lin clinic trial result
potenti nda submiss rux cream ad
potenti present full trial result scientif meet
potenti report initi true-v clinic trial result
potenti submiss tafasitamab dlbcl
potenti approv tafasitamab dlbcl
potenti initi dose escal dose expans trial tafasitamab plu parsaclisib
r/r nhl cll
potenti approv capmatinib novarti nsclc c-met-mutation-posit
potenti report data parsaclisib fl mcl mzl
potenti report data metastat squamou carcinoma anal canal
potenti report initi data solid tumor
wilmington delaware-bas incyt corpor drug discoveri develop compani grow pipelin novel small-molecul
drug treat variou inflammatori disord cancer
risk invest thesi valuat includ clinic develop competit regulatori sector
clinic develop risk drug develop riski capital-intens endeavor major drug enter clinic develop
fail reach market
competit risk drug market develop condit program address lack
differenti clinic data drug and/or approv competit drug may advers impact sale potenti product
regulatori risk like drug develop compani reliant upon fda pace evalu new drug agenc
willing approv new drug
sector risk valuat biotechnolog stock subject investor assess prospect underli compani investor
toler risk confid prospect biotechnolog stock group therefor stock price may fall even
compani meet exce investor expect
